Biocon Limited — Q3 FY24
Biocon's Q3 FY24 consolidated revenue from operations grew 34% YoY to INR 3,954 crore, driven by a 65% surge in biosimilars revenue, partially offset by a 7% decline in generics.
neutral
medium
✓ Verified against BSE filing
Indian management teams deliver on roughly 12% of specific earnings-call promises. A low score does not indicate dishonesty — it reflects how aspirational forward guidance typically is.
Q2 FY24
Biocon Biologics to deliver $1 billion revenue in FY24
Management reaffirmed full-year revenue guidance of $1 billion for Biocon Biologics, driven by market share gains and new product launches.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1
Q2 FY24
Generics H2 performance to improve over H1
Generics business expects improved second half performance, with formulations steady at ~INR 400 crore per half and API recovery, but full-year growth revised to low teens/high single digit.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1
Q2 FY24
Ustekinumab filing on track by end of 2023
Biocon Biologics remains on track to file ustekinumab (Stelara biosimilar) before the end of 2023, with denosumab filing expected by end of next year.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1